SCHEDULE: Farallon Capital Amends Crinetics Pharma Stake, Updates Management
Ownership Disclosure
Farallon Capital and its affiliates have filed an amended Schedule 13G for Crinetics Pharmaceuticals, Inc., reporting an 8.5% beneficial ownership and detailing recent management changes within Farallon.
Summary
- Farallon Capital Partners, L.P. and its affiliated entities (collectively, the "Farallon Funds") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Crinetics Pharmaceuticals, Inc.
- The Farallon group, through various funds and their general partners, collectively holds 8,024,098 shares of Crinetics Pharmaceuticals, Inc. common stock.
- This aggregate ownership represents 8.5% of the class of securities, as reported by the individual managing members/managers of the Farallon entities.
- Farallon Partners, L.L.C., as the general partner for several Farallon Funds, is deemed a beneficial owner of 7,826,338 shares, representing 8.2% of the class.
- The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing control of Crinetics Pharmaceuticals, Inc.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor is maintaining a substantial stake, which can be interpreted as a vote of confidence in Crinetics Pharmaceuticals, Inc. The management changes within Farallon are internal and do not directly reflect on the issuer.
Positives
- A significant institutional investor, Farallon Capital, maintains a substantial 8.5% stake in Crinetics Pharmaceuticals, Inc., indicating continued confidence in the company.
Negatives
- No specific negative financial or operational information about Crinetics Pharmaceuticals, Inc. is disclosed in this ownership filing.
Risks
- No specific risks related to Crinetics Pharmaceuticals, Inc. are mentioned in this ownership disclosure filing.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Crinetics Pharmaceuticals, Inc.'s future performance or operations.
Industry Context
StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into significant investor positions. Farallon Capital Management, L.L.C. is a prominent hedge fund, and its continued substantial stake in Crinetics Pharmaceuticals, Inc. (a biotechnology company) suggests a long-term investment thesis in the sector, potentially driven by the company's pipeline or market position.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Member/Manager of Farallon entities | NA | Avner A. Husen | 2026-01-01 | Became a member/manager, deemed a beneficial owner of shares held by Farallon Funds. |
| Managing Member/Manager of Farallon entities | Richard B. Fried | NA | 2025-12-31 | Ceased to be a member/manager, no longer deemed a beneficial owner of shares held by Farallon Funds. |
| Managing Member/Manager of Farallon entities | Rajiv A. Patel | NA | 2025-12-31 | Ceased to be a member/manager, no longer deemed a beneficial owner of shares held by Farallon Funds. |
| Managing Member/Manager of Farallon entities | William Seybold | NA | 2025-12-31 | Ceased to be a member/manager, no longer deemed a beneficial owner of shares held by Farallon Funds. |
Stakeholder Impact
- Shareholders of Crinetics Pharmaceuticals, Inc. may view the continued significant stake by Farallon Capital as a positive indicator of institutional confidence.
- The internal management changes within Farallon Capital do not directly impact Crinetics Pharmaceuticals, Inc.'s employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Date of event which requires filing of this statement (ownership snapshot date). |
| 2025-12-31 | Effective date for Richard B. Fried, Rajiv A. Patel, and William Seybold ceasing to be managing members/managers of Farallon entities. |
| 2026-01-01 | Effective date for Avner A. Husen becoming a managing member/manager of Farallon entities. |
| 2026-02-05 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Recommendation
holdThe filing indicates a significant institutional investor, Farallon Capital, maintains a substantial 8.5% stake in Crinetics Pharmaceuticals, Inc. This continued ownership by a sophisticated investor suggests a positive long-term view, but the filing itself is an ownership disclosure and does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. The internal management changes within Farallon do not directly affect the investment thesis for Crinetics. Therefore, a 'hold' recommendation is appropriate, acknowledging the institutional backing without new catalysts.
Keywords
Crinetics Pharmaceuticals, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, CRNX, Biotechnology, Pharmaceuticals, Equity Stake, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.